Site selection can make or break a clinical investigation. In most medical device studies, the sponsor selects the sites. Sponsors often have long-standing relationships with physicians, a hospital that took part in earlier studies, or strategic and marketing reasons to work with a particular center.
But is the familiar choice always the best one? As a CRO, we are rarely the ones choosing the sites, but our CRAs are the ones who work with them every day. We see first-hand which sites deliver clean data on time and which ones struggle. If the choice were ours, these are the factors we would look at before signing up a site.
The single biggest predictor of site performance we see is the study team, not the principal investigator alone. Medical device studies rarely have the resources of pharmaceutical trials. Pharma sites typically have dedicated, experienced study coordinators. That extra capacity lowers the risk of communication gaps, slow query resolution, late safety reporting and errors.
Device studies look different. Patient populations are often smaller, budgets are tighter, and the site team frequently consists of the PI, perhaps a sub-investigator, and PhD students or nurses who handle the day-to-day work. A dedicated study coordinator is the exception rather than the rule, and when there is one, they are often stretched across several studies.
Without a coordinator, physicians and nurses fit study tasks around their clinical work. That sounds feasible on paper, but it rarely works in practice. Patient care always comes first, and shift work, holidays and sick leave all take their toll. The result is an increased risk of slow responses, a growing query backlog and, at worst, safety events that are not reported on time. For the CRA, it can feel like bailing water out of a leaking boat: however hard you work, the problems keep coming.
Our advice to sponsors: do not select a site on the strength of the PI relationship alone. During feasibility, ask who will do the daily study work, how many hours per week they can commit and how many other studies they are running. A great PI with no time and no team will cost you more in delays than you gain from the relationship. This is not just good practice: ISO 14155 expects the sponsor to verify, before a site starts, that the principal investigator has adequate resources, including a qualified site team, and access to enough suitable subjects.
A site can only enroll the patients it actually sees. Over-optimistic enrollment estimates remain one of the most common reasons studies fall behind schedule. Before selecting a site, discuss realistic enrollment rates and ask for evidence, such as the number of eligible patients treated in the past year.
Pay particular attention to stratification. If your protocol stratifies by sex, age group or disease subtype, check that the site can recruit across all strata. A site that mainly treats one subtype of a condition may enroll quickly but skew your ratios, leaving other sites, or the study as a whole, struggling to balance the dataset.
Useful questions to ask during feasibility:
Hospital pharmacies, which often manage device storage and dispensing, play a central role in device accountability, and they do not always fall under the PI's influence.
In some EU countries, hospital pharmacies operate very independently from the clinical departments. Scheduling a monitoring visit to check device accountability takes time, and a request from the PI has only a limited effect.
The solution is to address it during site set-up. Make sure the clinical investigation agreement, or a separate arrangement with the pharmacy, clearly covers their responsibilities, contact persons and availability for monitoring visits. The same applies to other supporting departments the study depends on, such as radiology or the laboratory. Having these commitments in writing gives you something to fall back on when communication stalls.
Sponsors tend to return to the same sites, and often the same handful of countries, study after study. As a result, these sites are often running several competing studies for the same patients and have little capacity left.
Sites and countries that are selected less often can offer real advantages: motivated investigators, less competition for patients and teams with more time to dedicate to your study. Ask whether a regional hospital instead of a large academic center, or a less obvious country, could reach your enrollment targets faster. Factor in each country's ethics and competent authority requirements, but do not let unfamiliarity alone rule a site or country out. They might surprise you.
Choosing the right sites early saves time, budget and frustration throughout your clinical investigation. As a specialized medical device and IVD CRO, Qserve can support you from the very first step through to study close-out. Before the study starts, we run feasibility assessments, conduct site qualification visits and evaluate not only the PI, but also the site team's capacity, patient population and supporting departments. Once the study is running, our CRAs monitor your sites and keep data quality, query resolution and safety reporting on track. With CRAs based across Europe, we can support you both in the countries you already work with and in countries beyond your usual choices, wherever your study takes you. Find out more about our clinical investigation services for medical devices and IVD and how we can help you build a site network that delivers.